Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acuity Pharmaceuticals has completed the patient dosing component of its phase II clinical program for Cand5, its lead RNA interference product candidate for the treatment of a serious eye condition that causes adult blindness.
Subscribe to our email newsletter
According to the company, the trial of the drug in wet age-related macular degeneration (AMD) is the first ever phase II efficacy trial for a small interfering RNA therapy – an innovative approach that works by selectively silencing genes.
The company has also begun dosing patients in a pilot phase II trial of Cand5 in its second indication of diabetic macular edema (DME).
“Investigator recognition of the therapeutic potential of Acuity’s novel gene silencing drug facilitated achievement of our enrollment targets for this pioneering phase II study in wet AMD,” said Dr Lawrence Singerman of Retina Associates of Cleveland, and an investigator in the studies.